Summary
LIBRA PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €1.2m and a net result of €137,007. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 35% of 6,680 sector peers (NACE 64, financial year 2025). The company has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Directors
2 directors, last change in 2024
Esmoreit De Neef
CurrentDirector (not named in the articles) · since 01-07-2024
BYTEBIER Kaatje
CurrentDirector
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
2 of this company's 4 Belgian Official Gazette deeds have not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.
Mandate history
2 people since 2023, 2 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| BYTEBIER Kaatje |
|
| Esmoreit De Neef |
|
Owners and capital
Capital and shareholders
Capital over the years
- 25-08-2023 Capital stated in the deed · 186 shares